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It was revealed the overfilled genome region was 8q24.21.
Association with prostate cancer was found with 17 SNPs. 8 SNPs
had the intergenic localization: SRRM1P1–CCAT1 (rs16901979,
rs12682344, rs6983561, rs10505483) and CASC8–CASC11
(rs10090154, rs4242384, rs7837688, rs4242382); 9 SNPs – intragenic
location: PRNCR1 (rs1016343, rs1456315, rs13254738, rs13252298),
LOC101930033 (rs445114, rs16902094, rs10505477), CCAT2
(rs6983267), CASC8 (rs1447295).
The early development of the disease was associated with the
9 SNPs: 4 SNPs were located in genes, 5 SNPs had the intergenic
localization. It was noted among 9 SNPs 4 markers were in
11q13.3 region (rs7127900, rs7126629, rs7931342, rs11228583).
5 markers (rs6983267, rs10993994, rs7127900, rs7931342,
rs17632542) have found in prostate cancer patients and in group
of patients with early development.
The 7 SNPs had the association with PSA level (rs16856139,
rs12409639, rs10993994, rs3213764, rs1058205, rs1354774,
rs2735839). 1 SNP among them was located intergenic region
(KLK3–KLK2 rs2735839), 6 SNPs – were in genes (SLC45A3
rs16856139, rs12409639, MSMB rs10993994, ATF7I rs3213764,
KLK3 rs1058205, KLKP1 rs1354774). 2 SNPs from 7 (rs10993994,
rs2735839) had the relation to PSA level and to prostate cancer
patients. Polymorphic variant rs10993994, located near 50-UTR
MSMB gene, had the associations with prostate cancer patients,
patients with early start of disease and with PSA level.
In conclusion, the search of genetic markers of prostate cancer
development is actual inmodern oncology. These data will allow
to form the groups of patients with different outcome and prog-
nosis and perform the personalized therapy for every patient.
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Background: Intratumoral heterogeneity contributes signifi-
cantly to the effectiveness of cancer treatment and outcome (Ng
C.K., Pemberton H.N., Reis-Filho J.S., 2012). Previously the phe-
nomenon of intratumoral morphological heterogeneity was
demonstrated in breast cancer and it was found that the presence
of alveolar structures in breast tumors is associated with high fre-
quency of lymphogenic metastasis (Zavyalova M.V. et al., 2013a;
Zavyalova M.V. et al. 2013b; Denisov E.V. et al., 2014). Tumor
microenvironment (ME) is a key factor in determining the proper-
ties of the invasive and metastatic potential of the tumor and
seems to be also heterogeneous. Analysis of the ME in patients
with different solid tumors reveals that the majority of tumors
show a T cell–infiltrated phenotype. Macrophages, fibroblasts,
dendric cells etc. are also located in the ME and show their
effects. The aim of this work was to determine the expression
of key markers of cells which are presented in the ME of the var-
ious morphological structures.
Materials and methods: A 49 year-old patient (IC NST, luminal
A, T1NxMx, grade 2) was enrolled in this study. The ME of tubular
(hollow-like), alveolar (morula-like), trabecular, solid structures/
patterns, and discrete (small) groups of tumor cells were isolated
from invasive breast carcinoma NST (n = 1) using laser microdis-
section (PALM, Carl Zeiss). RNA was extracted using RNeasy Plus
Micro Kit (Qiagen, USA) according to the manufacturer’s instruc-
tions. cDNA was synthesized, ligated, and amplified using
QuantiTect Whole Transcriptome Kit (Qiagen, USA) according to
the manufacturer’s instructions. The gene expression of ALCAM,
Bcl6, CD3E, CD4, CHI3L2, CHID1, FAP, CD244, FoxP3, RORc, CD8,
GATA-3, TBX21, EPCAM, CD79, CD206, CD209, IL12, CXCL11, TGFb,
IL10 was analyzed using qRT-PCR and normalized to ACTB1 gene
and normal tissue.
Results: We showed the prevalence of gene expression in the
ME of alveolar and solid structures. At the same time only one
gene (GATA-3) was found to be expressed in the ME of trabecular
structures and discrete groups of tumor cells. In the ME of alveo-
lar structures we found transcripts involved in Th1-response
(CD3E, CD4 and CD8). In addition, expression of GATA-3, TGFb,
FAP (fibroblast marker) and CD79 (B-lymphocyte marker) genes
linked with the Th2-response was also shown in the ME of
alveolar structures. In the ME of solid structures we detected
expression of CD3E gene (lymphocyte marker), transcription
factors of Th1, Th2 and Th17 cells (TBX21, GATA-3 and RORc
genes, respectively), NK cell marker (CD244), fibroblast marker
(ALCAM), and IL12 gene.
Conclusion: The obtained data demonstrate heterogeneity of
the tumor microenvironment in invasive breast carcinoma NST.
Inflammatory (Th1-response) and anti-inflammatory (Th2) reac-
tions were observed both in the ME of alveolar and solid struc-
tures. The ME of trabecular structures and discrete groups of
cancer cells showed only inflammatory marker. Functional
activity of the ME of alveolar structures is determined by expres-
sion of TGFb gene, which is involved in anti-inflammatory
response, invasion and progression, while in the microenviron-
ment of solid structures IL-12 gene, a key cytokine of Th1
response is expressed.
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Glucocorticoids (GCs) are the most important component of
therapy for a number of diseases including combined chemother-
apy of hematological malignancies. However, their application is
strongly restricted by the development of serious side effects as
well as glucocorticoid resistance. Both side effects and resistance
affect child cancer patients more intensively.
Adverse side-effects of glucocorticoid treatment are the result
of glucocorticoid receptor (GR)-mediated gene activation,
while the beneficial anti-inflammatory effects result from
GR-mediated ‘transrepression’. Difference in mechanisms of
therapeutic and side effects of GCs became obvious and selective
glucocorticoid agonists (SEGRA) were developed aiming to sepa-
rate transactivation from transrepression. Recently we have
demonstrated that one of the modern SEGRAs, 2-(4-acetoxyphenyl)-
2-chloro-N-methyl-ethylammonium chloride or CpdA, selectively
induces transrepression in lymphoma cells and reveals GR-
dependent anti-lymphoma activity in vitro and in vivo. However,
CpdA is a chiral molecule and exists as a racemic mixture of two
enantiomers. Enantiomers often possess the same physical and
chemical properties but their biological effects may differ drastically.
They differently interact with cell receptors and it can lead to the
essential diversity in pharmacokinetics and pharmacodynamics.
The notorious example of such a molecule is Thalidomide which
was originally designed and used as a sedative drug during the preg-
nancy, but it was withdrawn chiefly because of its severe terato-
genicity. As it was demonstrated, only (R)-thalidomide exhibited
significant sedative effects, while (S)-thalidomide revealed the ter-
atogenic effects. The application of enantiopure compounds may
lead to reduction of metabolism variability in patients and to
decrease of drug effective dose. Thereby, the synthesis of enantiop-
ure isomers of CpdA and the study of their anti-cancer activity are of
immediate interest in cancer research.
We synthesized for the first time enantiomers of the CpdA
based on literature precedent Sharpless asymmetric dihydroxyla-
tion with AD-mix-alpha or AD-mix-beta. (S)- and (R)-enantiomers
with enantiopure excess of 98% were obtained. Then we evalu-
ated the cytotoxic effects on acute lymphoblastic leukemia cells
CEM and mantle cell lymphoma cells Granta by direct cell count-
ing and found that cytotoxic activities of both enantiomers were
comparable with the effect of racemic mixture on cell growth and
survival. Glucocorticoids modulate the expression of genes
through transrepression and transactivation mechanisms
realized in equal measure. In present work we estimated the
potential ability of newly synthesized enantiomers to activate
these mechanisms.
Transactivation realizes through direct binding of receptor
homodimers to specific sequences (glucocorticoid responsive ele-
ments (GREs)) in promoter or enhancer regions of GR target genes.
Therefore, we studied the level of transactivation as the expres-
sion of GR-regulated genes, immunophiline FKBP51 and
glucocorticoid-induced leucine zipper GILZ. As shown by Q-RT-
PCR, the expression of FKBP51 and GILZ was unaffected after cell
treatment by both CpdA enantiomers; hence, these compounds
did not induce GR transactivation.
GR-transrepression is chiefly mediated by protein–protein
interaction between GR and other transcription factors like NF-
kB and AP1, followed by inhibition of their transcriptional activity.
We evaluated the transrepression by expression of NF-kB-
depended genes, cyclines D1 and D2 (CCND and CCND2).
(S)-enantiomer of CpdA down-regulated the expression of CCND1
and CCND2 to the level compared with Dex while (R)-enantiomer
surprisingly increased level of CCND1 and CCND2 expression.
This fact demonstrated that (S)-CpdA is perspective as
antiproliferative and cell growth inhibiting agent.
Overall, our data provide the potential for further studies of




Morphological characteristics and clinical significance of tumor infil-
trating CD20 B lymphocytes in gastric cancer
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The expression features of CD20 B-cells in gastric cancer (GC)
are not well understood. The aim of the study was to give
morphological characteristics of CD20 tumor infiltrating
B-lymphocytes (TIL) and evaluate their clinical significance.
We studied the samples of gastric mucosa (GM) adjacent to
tumor in 35 patients with gastric cancer who had undergone rad-
ical surgery (R0) in Orenburg Regional Clinical Oncology Center
between January 2009 and July 2010. The sections were stained
immunohistochemically using antibodies to CD20. The density
of CD20 B-lymphocytes was calculated using the relative area unit
(RAU) equal to 0.42  0.28 mm2 with the magnification400.
We observed 3 types of structures in which the expression of
CD20 B lymphocytes was analyzed: individual cells located dif-
fusely in the GM and the tumor stroma, focal lymphoid infiltrates
(LI) and lymphoid follicles (LF). Cells expressing CD20 were of 2
types: round shape with sharp profile and a narrow rim of cyto-
plasm and irregularly shaped cells with indistinct contours and
lots of cytoplasmic processes. There were 8 patients with atypical
marked LF germinal center (AGC) arranged around the periphery
of the follicle and irregularly shaped. AGC cells had large bright
nucleus of round shape with distinct chromatin clumps and did
not express CD20.
Correlation between density of CD20 B-lymphocyte in GM and
depth of tumor invasion (gamma = 0.474, p = 0.01) and the num-
ber of lymph node metastases was found (gamma = 0.603,
p = 0.008). The lowest density value of CD20 B-lymphocytes was
observed in three or more metastases (N2) in lymph node
(56 + 19.5 + 30.3 + 16.4 and 26.9 + 16.1 cells per unit of area,
respectively, with N0, N1 and N2, p = 0.003) and depth of invasion
G3-4 (55.7 + 19.7 and 32.8 + 19.7 cells per unit of area, respectively,
for G1-2 and G3-4, p = 0.02).
In turn, the presence of focal LI correlated with the degree of
differentiation (gamma = 0.525, p = 0.02) and three-year overall
survival (gamma = 0.738, p = 0.03); the presence of LF correlated
with the Grade (gamma = 0.525, p = 0.02), histological type
(gamma = 0.600, p = 0.03) and the three-year relapse-free survival
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